medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-33-50-56medalphabet-3511Research ArticleСтатьиСостояние когнитивных функций у полиморбидных пациентов с артериальной гипертензией, фибрилляцией предсердий и хронической болезнью почекCognitive function status in polymorbid patients with arterial hypertension, atrial fibrillation and chronic kidney diseasehttps://orcid.org/0000-0001-6823-6077ШаталоваН. А.ShatalovaN. A.

Шаталова Наталья Андреевна, ассистент кафедры терапии и полиморбидной патологии имени академика М. С. Вовси

Москва

Shatalova Natalya A., assistant at Dept of Therapy and Multimorbid Pathology n. a. academician M. S. Vovsi

Moscow

https://orcid.org/0000-0002-8941-7018ДзамиховК. К.DzamikhovK. K.

Дзамихов Кантемир Каральбиевич, аспирант кафедры терапии и полиморбидной патологии имени академика М. С. Вовси

Москва

Dzamikhov Kantemir K., graduate student of Dept of Therapy and Multimorbid Pathology n. a. academician M. S. Vovsi

Moscow

https://orcid.org/0000-0001-5801-3742КочетковА. И.KochetkovA. I.

Кочетков Алексей Иванович, к. м. н., доцент кафедры терапии и полиморбидной патологии имени академика М. С. Вовси

Москва

Kochetkov Alexey I., PhD Med, associate professor at Dept of Therapy and Multimorbid Pathology n. a. academician M. S. Vovsi

Moscow

https://orcid.org/0000-0003-1316-7654БатюкинаС. В.BatyukinaS. V.

Батюкина Светлана Владимировна, ассистент кафедры терапии и полиморбидной патологии имени академика М. С. Вовси

Москва

Batyukina Svetlana V., assistant at Dept of Therapy and Multimorbid Pathology n. a. academician M. S. Vovsi

Moscow

batyukina.svetlana@yandex.ruhttps://orcid.org/0000-0001-6573-4169ЭбзееваЕ. Ю.EbzeyevaE. Y.

Эбзеева Елизавета Юрьевна, к. м. н., доцент кафедры терапии и полиморбидной патологии имени академика М. С. Вовси

Москва

Ebzeeva Elizaveta Yu., PhD Med, associate professor at Dept of Therapy and Multimorbid Pathology n. a. academician M. S. Vovsi

Moscow

https://orcid.org/0000-0002-0795-8225ОстроумоваЕ. Ю.OstroumovaO. D.

Остроумова Ольга Дмитриевна, д. м. н., проф., зав. кафедрой терапии и полиморбидной патологии имени академика М. С. Вовси, проф. кафедры клинической фармакологии и пропедевтики внутренних болезней

Москва

Ostroumova Olga D., DM Sci (habil.), professor, head of Dept of Therapy and Multimorbid Pathology n. a. academician M. S. Vovsi1, professor at Dept of Clinical Pharmacology and Propaedeutics of Internal Diseases

Moscow

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy for Continuing Professional EducationRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России (Сеченовский университет)РоссияRussian Medical Academy for Continuing Professional Education; I. M. Sechenov First Moscow State Medical UniversityRussian Federation202319012024033Неврология и психиатрия (4)5056Copyright © Шаталова Н.А., Дзамихов К.К., Кочетков А.И., Батюкина С.В., Эбзеева Е.Ю., Остроумова Е.Ю., 20242024Шаталова Н.А., Дзамихов К.К., Кочетков А.И., Батюкина С.В., Эбзеева Е.Ю., Остроумова Е.Ю.Shatalova N.A., Dzamikhov K.K., Kochetkov A.I., Batyukina S.V., Ebzeyeva E.Y., Ostroumova O.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3511

Обоснование. Когнитивные нарушения являются одной из проблем общественного здравоохранения. Полиморбидные пациенты с артериальной гипертензией (АГ), фибрилляцией предсердий (ФП) и хронической болезнью почек (ХБП) подвергаются высокому риску развития когнитивных нарушений, что приводит к ухудшению качества жизни, трудностям в соблюдении режима приема лекарств и повышенному риску смертности.Цель исследования. Оценка когнитивного статуса полиморбидных пациентов в возрасте 60 лет и старше с эссенциальной АГ и ФП в зависимости от наличия и стадии ХБП.Материалы и методы. Включены 165 пациентов в возрасте 60 лет и старше с эссенциальной АГ и ФП (80 [48,5 %] мужчин, 85 (51,5 %) женщин; средний возраст составил 82 [76; 85] года), которые были разделены на три группы в зависимости от наличия и стадии ХБП: 55 (33,3 %) пациентов с АГ и ФП без ХБП, 55 (33,3 %) пациентов с АГ, ФП и ХБП С3а и 55 (33,3 %) пациентов с АГ, ФП и ХБП С3б. Всем пациентам, включенным в настоящее исследование, было проведено исследование когнитивных функций с помощью ряда нейропсихологических тестов.Результаты. При исследовании когнитивных функций (краткая шкала оценки психического статуса – КШОПС, шкала оценки болезни Альцгеймера – ADAS-cog, тест замены цифровых символов – DSST, тест литературных ассоциаций) обнаружено, что выраженность когнитивных нарушений нарастала по мере увеличения стадии ХБП.Вывод. Полученные результаты исследования свидетельствуют о неблагоприятном влиянии ХБП на когнитивные функции у пациентов пожилого и старческого возраста с АГ и ФП. Таким образом, существует необходимость регулярного наблюдения и обследования пациентов с сопутствующей ХБП на предмет наличия когнитивных нарушений.

Background. Cognitive impairment is a public health problem. Polymorbid patients with arterial hypertension (AH), atrial fibrillation (AF), and chronic kidney disease (CKD) are at high risk of developing cognitive impairment, resulting in impaired quality of life, difficulty in medication adherence, and increased risk of mortality.Objective. To evaluate the cognitive status of polymorbid patients aged 60 years and older with essential AH and FP depending on the presence and stage of CKD.Materials and methods. 165 patients aged 60 years and older with essential AH and AF (80 [48.5 %] men, 85 [51.5 %] women, mean age was 82 [76; 85] years) were included and divided into three groups depending on the presence and stage of CKD: 55 (33.3 %) patients with AH and AF without CKD, 55 (33.3 %) patients with AH, AF, and CKD C 3a, and 55 (33.3 %) patients with AH, AF, and CKD C 3b. All patients included in the present study were examined for cognitive functions using a series of neuropsychological tests.Results. In the study of cognitive functions (Mini-mental State Examination, MMSE, Alzheimer Disease Assessment Scale-Cognitive (ADAS-cog), Digit Symbol Substitution Test (DSST), literature Association Test), it was found that the severity of cognitive impairment increased with increasing stage of CKD.Conclusions. The obtained results of the study indicate an unfavorable effect of CKD on cognitive functions in elderly and elderly patients with AH and FP. Thus, there is a need for regular monitoring and examination of patients with concomitant CKD for cognitive impairment.

когнитивные нарушенияхроническая болезнь почекартериальная гипертензияфибрилляция предсердийcognitive disorderschronic kidney diseasearterial hypertensionatrial fibrillationReferencesDunn R., Clayton E., Wolverson E., Hilton A. Conceptualising comorbidity and multimorbidity in dementia: A scoping review and syndemic framework. J Multimorb Comorb. 2022; 12: 26335565221128432. https://doi.org/10.1177/26335565221128432Dunn R., Clayton E., Wolverson E., Hilton A. Conceptualising comorbidity and multimorbidity in dementia: A scoping review and syndemic framework. J Multimorb Comorb. 2022; 12: 26335565221128432. https://doi.org/10.1177/26335565221128432Guidelines World Health Organization. Risk Reduction of Cognitive Decline and Dementia; 2019.Guidelines World Health Organization. Risk Reduction of Cognitive Decline and Dementia; 2019.Оганов Р. Г., Симаненков В. И., Бакулин И. Г., Бакулина Н. В., Барбараш О. Л., Бойцов С. А., Болдуева С. А., Гарганеева Н. П., Дощицин В. Л., Каратеев А. Е., Котовская Ю. В., Лила А. М., Лукьянов М. М., Морозова Т. Е., Переверзев А. П., Петрова М. М., Поздняков Ю. М., Сыров А. В., Тарасов А. В., Ткачева О. Н., Шальнова С. А. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18 (1): 5–66.Oganov R. G., Simanenkov V. I., Bakulin I. G., Bakulina N. V., Barbarash O. L., Boytsov S. A., Boldueva S. A., Garganeeva N. P., Doshchitsin V. L., Karateev A. E., Kotovskaya Yu.V., Lila A. M., Lukyanov M. M., Morozova T. E., Pereverzev A. P., Petrova M. M., Pozdnyakov Yu.M., Syrov A. V., Tarasov A. V., Tkacheva O. N., Shalnova S. A. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019; 18 (1): 5–66. (In Russ.) https://doi.org/10.15829/1728–8800–2019–1–5–66Waldstein S. R., Giggey P. P., Thayer J. F., Zonderman A. B. Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension. 2005; 45 (3): 374–9. https://doi.org/10.1161/01.hyp.0000156744.44218.74Waldstein S. R., Giggey P. P., Thayer J. F., Zonderman A. B. Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension. 2005; 45 (3): 374–9. https://doi.org/10.1161/01.hyp.0000156744.44218.74Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M, Horton R, Burkhardt JD, Lakkireddy D, Reddy YM, Casella M, Dello Russo A, Tondo C, Natale A. Atrial fibrillation and the risk of incident dementia: A meta-analysis. Heart Rhythm. 2012; 9 (11): 1761–8. https://doi.org/10.1016/j.hrthm.2012.07.026Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M, Horton R, Burkhardt JD, Lakkireddy D, Reddy YM, Casella M, Dello Russo A, Tondo C, Natale A. Atrial fibrillation and the risk of incident dementia: A meta-analysis. Heart Rhythm. 2012; 9 (11): 1761–8. https://doi.org/10.1016/j.hrthm.2012.07.026Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, Kumaraswami L, Liakopoulos V, Rakhimova Z, Saadi G, Strani L, Ulasi I, Kalantar-Zadeh K. Kidney health for everyone everywhere – from prevention to detection and equitable access to care. Clin Nephrol. 2020; 93 (3): 111–122. https://doi.org/10.5414/cnwkdeditorialLi PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, Kumaraswami L, Liakopoulos V, Rakhimova Z, Saadi G, Strani L, Ulasi I, Kalantar-Zadeh K. Kidney health for everyone everywhere – from prevention to detection and equitable access to care. Clin Nephrol. 2020; 93 (3): 111–122. https://doi.org/10.5414/cnwkdeditorialEtgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: A systematic review and meta-analysis. Am J Nephrol. 2012; 35 (5): 474–82. https://doi.org/10.1159/000338135Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: A systematic review and meta-analysis. Am J Nephrol. 2012; 35 (5): 474–82. https://doi.org/10.1159/000338135Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53 (4): 695–9. https://doi.org/10.1111/j.1532–5415.2005.53221.xNasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53 (4): 695–9. https://doi.org/10.1111/j.1532–5415.2005.53221.xFolstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12 (3): 189–98. https://doi.org/10.1016/0022–3956(75)90026–6Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12 (3): 189–98. https://doi.org/10.1016/0022–3956(75)90026–6Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141 (11): 1356–64. https://doi.org/10.1176/ajp.141.11.1356Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141 (11): 1356–64. https://doi.org/10.1176/ajp.141.11.1356Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958. Vol. 8. P. 271–276.Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958. Vol. 8. P. 271–276.Wechsler D. The Measurement of Adult Intelligence. Baltimore, MD: The Williams & Wilkins Company; 1939.Wechsler D. The Measurement of Adult Intelligence. Baltimore, MD: The Williams & Wilkins Company; 1939.Wechsler D. Nederlandstalige bewerking, afname-en scorings handleiding [the Dutch version of the WAIS-IV: Administration and scoring manual]. 2012.Wechsler D. Nederlandstalige bewerking, afname-en scorings handleiding [the Dutch version of the WAIS-IV: Administration and scoring manual]. 2012.Strauss E. A compendium of neuropsychological tests: Administration, Norms, and Commentary. E. Strauss. 3d edition. Oxford: Oxford University Press, 2006. 1240 p.Strauss E. A compendium of neuropsychological tests: Administration, Norms, and Commentary. E. Strauss. 3d edition. Oxford: Oxford University Press, 2006. 1240 p.Kaplan E., Goodglass H., & Weintraub S. (1983). The Boston Naming Test. Philadelphia, PA: Lea & Fibiger.Kaplan E., Goodglass H., & Weintraub S. (1983). The Boston Naming Test. Philadelphia, PA: Lea & Fibiger.MacLeod CM. Half a century of research on the Stroop effect: An integrative review. Psychol Bull. 1991 Mar; 109 (2): 163–203. https://doi.org/10.1037/0033–2909.109.2.163MacLeod CM. Half a century of research on the Stroop effect: An integrative review. Psychol Bull. 1991 Mar; 109 (2): 163–203. https://doi.org/10.1037/0033–2909.109.2.163Ganesan V, Sethuraman K, Sureshkumar, Prabhu V. Platelet glycogen synthase kinase 3β regulates plasma β amyloid and phosphorylated tau levels in chronic kidney disease patients with cognitive dysfunction; therapeutic role of erythropoietin. J Nephropathol. 2023; 12 (4): e17238. https://doi.org/10.34172/jnp.2022.17238Ganesan V, Sethuraman K, Sureshkumar, Prabhu V. Platelet glycogen synthase kinase 3β regulates plasma β amyloid and phosphorylated tau levels in chronic kidney disease patients with cognitive dysfunction; therapeutic role of erythropoietin. J Nephropathol. 2023; 12 (4): e17238. https://doi.org/10.34172/jnp.2022.17238Xie Z, Tong S, Chu X, Feng T, Geng M. Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis. Kidney Dis (Basel). 2022; 8 (4): 275–285. https://doi.org/10.1159/000524475Xie Z, Tong S, Chu X, Feng T, Geng M. Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis. Kidney Dis (Basel). 2022; 8 (4): 275–285. https://doi.org/10.1159/000524475Gronewold J, Volsek M, Todica O, Kribben A, Bruck H, Hermann DM. Physical, cognitive and emotional factors contributing to quality of life, functional health and participation in community dwelling in chronic kidney disease. PLoS One. 2014; 9 (3): e91176. https://doi.org/10.1371/journal.pone.0091176Gronewold J, Volsek M, Todica O, Kribben A, Bruck H, Hermann DM. Physical, cognitive and emotional factors contributing to quality of life, functional health and participation in community dwelling in chronic kidney disease. PLoS One. 2014; 9 (3): e91176. https://doi.org/10.1371/journal.pone.0091176Рогова И. В., Фомин В. В., Дамулин И. В., Минакова Е. Г., Селиванова О. Ю., Шашкова Е. В., Петлева Ю. А. Клинические особенности и патогенетические механизмы формирования когнитивных нарушений при хронической болезни почек. Клиническая нефрология. 2013; (4): 27–32.Rogova I. V., Fomin V. V., Damulin I. V., Minakova E. G., Selivanova O. Y., Shashkova E. V., Petleva Y. A. Clinical features and pathogenetic mechanisms of formation of cognitive disorders in chronic kidney disease. Clinical Nephrology. 2013; (4): 27–32. (In Russ.)Karasavvidou D, Boutouyrie P, Kalaitzidis R, Kettab H, Pappas K, Stagikas D, Antonakis N, Tsalikakis D, Elisaf M, Laurent S. Arterial damage and cognitive decline in chronic kidney disease patients. J Clin Hypertens (Greenwich). 2018; 20 (9): 1276–1284. https://doi.org/.1111/jch.13350Karasavvidou D, Boutouyrie P, Kalaitzidis R, Kettab H, Pappas K, Stagikas D, Antonakis N, Tsalikakis D, Elisaf M, Laurent S. Arterial damage and cognitive decline in chronic kidney disease patients. J Clin Hypertens (Greenwich). 2018; 20 (9): 1276–1284. https://doi.org/.1111/jch.13350Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, Allman RM, Warnock DG, McClellan W. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 2008; 52 (2): 227–34. https://doi.org/10.1053/j.ajkd.2008.05.004Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, Allman RM, Warnock DG, McClellan W. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 2008; 52 (2): 227–34. https://doi.org/10.1053/j.ajkd.2008.05.004Xu H, Garcia-Ptacek S, Trevisan M, Evans M, Lindholm B, Eriksdotter M, Carrero Pharm JJ. Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study. Neurology. 2021; 96 (24): e2956–65 https://doi.org/10.1212/wnl.0000000000012113Xu H, Garcia-Ptacek S, Trevisan M, Evans M, Lindholm B, Eriksdotter M, Carrero Pharm JJ. Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study. Neurology. 2021; 96 (24): e2956–65 https://doi.org/10.1212/wnl.0000000000012113Brodski J, Rossell SL, Castle DJ, Tan EJ. A Systematic Review of Cognitive Impairments Associated with Kidney Failure in Adults Before Natural Age-Related Changes. J Int Neuropsychol Soc. 2019; 25 (1): 101–114. https://doi.org/10.1017/S 1355617718000917Brodski J, Rossell SL, Castle DJ, Tan EJ. A Systematic Review of Cognitive Impairments Associated with Kidney Failure in Adults Before Natural Age-Related Changes. J Int Neuropsychol Soc. 2019; 25 (1): 101–114. https://doi.org/10.1017/S 1355617718000917

The authors declare that there are no conflicts of interest present.